A Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission and Prevention of Structural Joint Damage During Treatment With Tocilizumab (TCZ), as a Monotherapy and in Combination With Methotrexate (MTX), Versus Methotrexate in Patients With Early, Moderate to Severe Rheumatoid Arthritis

Trial Profile

A Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission and Prevention of Structural Joint Damage During Treatment With Tocilizumab (TCZ), as a Monotherapy and in Combination With Methotrexate (MTX), Versus Methotrexate in Patients With Early, Moderate to Severe Rheumatoid Arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Tocilizumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms FUNCTION
  • Sponsors Roche
  • Most Recent Events

    • 16 Jun 2018 Results comparing pain and HAQ-DI from RA-BEGIN, PREMIER, ORAL-START, AMBITION and FUNCTION studies were presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results of pooled post-hoc analysis from four studies (AMBITION, ACT-RAY, ADACTA and FUNCTION) presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results determining the association of CXCL13 and sICAM1 with response to Tocilizumab and disease activity in early RA and DMARD IR patients subsets from the FUNCTION (early RA) and LITHE (DMARD IR) clinical trials presented at the 19th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top